Medicare AdvantageCoverageMedium impact
MA08.009x, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)
Independence Blue Cross·Allergy & Immunology, Hematology, Oncology +2 more·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.009x for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) has been updated with an effective date of January 1, 2026. This is a fresh policy change that may affect coverage, prior authorization, or billing requirements for immunoglobulin treatments.
Action Required
Before January 1, 2026: Billing team must review the complete MA08.009x policy at the source URL to identify specific changes to IVIG/SCIG coverage, prior authorization requirements, or billing procedures. Update billing system and staff training based on policy details once full content is reviewed.